Everolimus is a drug used to treat renal cell (kidney) cancer. It works by inhibiting mTOR, a protein that drives cancer growth. Yet for many patients, the cancer continues to grow. In this study, researchers are comparing the effectiveness of the investigational drug BMS-936558 with everolimus in patients with advanced or metastatic renal cell cancer which persists despite prior treatment with anti-angiogenic therapy (drugs which inhibit the development of blood vessels cancers need to grow and spread).
BMS-936558 boosts the body’s immune system by targeting a protein on white blood cells called PD-1. PD-1 normally maintains the balance of the immune system by shutting it down at the right time. Some cancers take advantage of this shut-down mechanism by activating PD-1, enabling them to escape attack by the body’s white blood cells. BMS-936558 binds to and inactivates PD-1, enhancing the body’s ability to detect and destroy cancer cells.
Patients will be randomly assigned to receive BMS-936558 or everolimus, but not both. Everolimus is given orally (by mouth), while BMS-936558 is given intravenously (by vein).